Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis
is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

Patients with unresectable hepatocellular carcinoma (HCC) usually have poor prognosis
because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are …

Hepatocellular carcinoma (HCC) is a common malignancy worldwide and sorafenib is a
standard of care therapeutics for unresectable HCC. Although sorafenib, a multikinase …

Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced
hepatocellular carcinoma (HCC). The present study was undertaken to determine whether …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Background Hepatocellular carcinoma (HCC) has a high incidence and mortality.
Radiotherapy and sorafenib have proven effective for HCC. Here, we investigated whether …

Background Sorafenib is recognized as a standard treatment for advanced hepatocellular
carcinoma (HCC). However, many patients have to adopt dose reduction or terminate the …